Image

North America Uterine Cancer Diagnostics Market – Industry Trends and Forecast to 2030

Medical Devices

Image

North America Uterine Cancer Diagnostics Market – Industry Trends and Forecast to 2030

  • Medical Devices
  • Published Report
  • Jan 2023
  • North America
  • 350 Pages
  • No of Tables: 242
  • No of Figures: 39

North America Uterine Cancer Diagnostics Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2023–2030
Diagram Market Size (Base Year) USD MILLION
Diagram Market Size (Forecast Year) USD 7,946.03
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

North America Uterine Cancer Diagnostics Market, By Diagnostic Type (Instrument Based And Procedure Based), Type (Endometrial Cancer And Uterine Sarcoma), Age Group (60), End User (Hospitals, Diagnostic Centers, Cancer Research Center, Ambulatory Surgical Centers, Specialized Clinics And Others), Distribution Channel (Direct Tender, Third Party Distributors and Others) - Industry Trends and Forecast to 2030.

North America Uterine Cancer Diagnostics Market

North America Uterine Cancer Diagnostics Market Analysis and Insights

Uterine cancer is the most common cancer that occurs in the female reproductive system. It is a malignant tumor that starts in the uterus cells and can spread to other body parts. According to research by the American Cancer Society (ACS), uterine sarcoma accounts for 5% of all uterine cancers worldwide, while endometrial cancer is the most common form of uterine cancer.

Uterine Cancer Diagnostics Market

Uterine Cancer Diagnostics Market

Data Bridge Market Research analyzes that the North America uterine cancer diagnostics market is expected to reach the value of USD 7,946.03 million by 2030, at a CAGR of 11.2% during the forecast period. Diagnostic type accounts for the largest segment in the market due to the increase in the obesity rate among the women population and rising uterine cancer patients North America. This market report also covers pricing analysis, patent analysis, and technological advancements in depth.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2020-2015)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

By Diagnostic Type (Instrument Based And Procedure Based), Type (Endometrial Cancer And Uterine Sarcoma), Age Group (<30, 31-40, 41-50, 51-60 And >60), End User (Hospitals, Diagnostic Centers, Cancer Research Center, Ambulatory Surgical Centers, Specialized Clinics And Others), Distribution Channel (Direct Tender, Third Party Distributors and Others)

Countries Covered

U.S., Canada, and Mexico

Market Players Covered

F-Hoffmann La Roche Ltd., Siemens Healthcare Private Limited, Narang Medical Limited, ESAOTE SPA, Olympus Corporation, Arquer Diagnostics Ltd, Guzip Biomarkers Corporation, General Electric, Canon Medical Systems ANZ Pty Limited., KARL STORZ, Medtronic, Stryker, Surtex Instruments Limited., Koninklijke Philips N.V., FUJIFILM Corporation, AED, Jalal Surgical, Integra LifeSciences, B. Braun Melsungen AG, and GRAIL among others

North America Uterine Cancer Diagnostics Market Definition

Diagnosis of uterine cancer includes ultrasound, biopsy procedures and blood tests. Ultrasound tests use sound waves and produce images of the ovaries and uterus. Two types of ultrasound are included in diagnostic testing for uterine cancer: abdominal ultrasound and transvaginal ultrasound. An abdominal scan test involves scanning the full bladder with a small probe across the abdomen, while a transvaginal scan involves inserting a probe tube into the vagina to scan or create an image. Biopsy procedures include endometrial biopsy, hysteroscopy and dilation and curettage.

Cancer is one of the leading causes of death worldwide and the prevalence of this disease has increased at an alarming rate. Therefore, health professionals are focusing on developing effective screening and treatment solutions to control obesity rates. Moreover, an endometrial biopsy involves removing some malignant tissue from the endometrium and sending it for a testing procedure. The growing number of geriatric women in the U.S. is also a major factor contributing to the growth of the uterine cancer diagnostic market.

North America Uterine Cancer Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail below:    

Drivers

  • Technological advancements in uterine cancer diagnostics

Uterine cancer is a ubiquitous gynaecological disease with many tests available for diagnosis, which include pelvic examination, endometrial biopsy, Dilation and Curettage (D&C), Transvaginal ultrasound, Computed Tomography (CT or CAT) scan, Magnetic Resonance Imaging (MRI) and biomarker testing of the tumor. Traditional means of detecting and monitoring cancers rely largely on imaging and, where possible, blood-based protein biomarkers, many of which are non-specific. Most cases of uterine cancer are diagnosed at late stages, as the presenting symptoms are often non-specific. The signs and symptoms of uterine cancer vary from person to person, making it difficult to provide accurate early diagnosis. This calls for personalized diagnostic plans, which involve multiple diagnostic tests.

Thus, technological advancements in uterine cancer diagnostics are expected to drive the market's growth.

  • Rising demand for minimally invasive advanced screening techniques

Uterine cancer, especially endometrial cancer, is the fifth most common cancer in women in very high human development index regions based on age-standardized rates and its incidence has increased over the last few years. The standard strategy to diagnose endometrial cancer consists of office-based pelvic ultrasonography plus endometrial papilla sampling in cases of increased endometrial thickness. A hysteroscopy is recommended when the diagnosis is uncertain. Limitations include sample insufficiency in unsuccessful insertions (on occasions due to cervical stenosis or prolapse) and as well an abnormal sonographic appearance of the endometrium. Hence several limitations are associated with so-called standard methods of a uterine cancer diagnosis.

Thus, rising demand for minimally invasive advanced screening techniques are expected to drive the market's growth.

Restraint

  • High risk complications during diagnostic tests

Several screening tests are used for detecting uterine cancers, which include the PAP test, transvaginal ultrasound and endometrial sampling (biopsy) among others. Although these tests are considered standard for diagnosing uterine cancer, they have their associated risks, including false-negative and false-positive results and side effects such as bleeding, discomfort, infection and puncture of the uterus.

As mentioned above, many complications are associated with the current diagnostic and screening tests for uterine cancer, which are keeping patients at further risk. These risks are expected to restrain the growth of the North America uterine cancer diagnostics market.

Opportunity

  • Increasing prevalence of uterine cancer

Uterine cancer is the most common type of gynecologic cancer. Over 90% of uterine cancers begin in the endometrium, the tissue lining the uterus. As the prevalence is increasing, the introduction of promising new treatments and therapeutic biologics and the rapid growth of hormone-resistant cancer drugs due to fewer side effects are also increasing. Awareness of the incidence of uterine cancer is growing among patients and healthcare providers, who are now becoming more active in learning about the diagnosis and treatments available for these diseases, which is expected to act as an opportunity for the market's growth.

Rates of new uterine cancer cases have risen 0.6% per year from 2010-2019 and death rates have risen an average of 1.7% per year for the /corp.html">same time frame. As the uterine cancer patient rate is increasing, the use of treatments and advanced technologies for cancer diagnosis will increase, which is an opportunity for market growth.

Challenge

  • Lack of diagnostic infrastructure

Non-communicable diseases such as uterine cancer and other types of cancer have now been recognized by the United Nations and WHO as major public health crises. Cancer is the biggest part of this problem and health systems face a major challenge to improve cancer care, control costs and increase system efficiency. Differences in treatment approaches and outcomes between high-income countries and low and middle-income countries are striking. Reasons for this disparity include cost, access to care, workforce and training gaps and lack of awareness among the lay and medical community. Diagnosis and treatment play an important role in this complex environment. Different regions and countries of the world have different health systems, but most of them are fragmented or poorly coordinated. There is an urgent need to expand cancer care in low- and middle-income countries.

Post-COVID-19 Impact on North America Uterine Cancer Diagnostics Market

The COVID-19 pandemic has caused disruptions in elective health services related to uterine screening, pre-cancer care and management of abnormal screening results. This could lead to an increase in the incidence of uterine cancer, exacerbating existing health inequalities.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launches and strategic partnerships to improve the technology and test results involved in the North America uterine cancer diagnostics market.

Recent Developments

  • In November 2022, Koninklijke Philips N.V., announced the North America launch of a next-generation compact portable ultrasound solution at the Radiological Society of North America (RSNA) annual meeting to bring the diagnostic quality associated with premium cart-based ultrasound systems to more patients. it is portable and versatile with good image quality or performance. it is compatible with Philips ultrasound systems Affiniti and EPIQ transducer. This has helped the company to expand its product portfolio
  • In April 2022, Medtronic and GE Healthcare announced a collaboration focused on the unique needs and demand for care at Ambulatory Surgery Centers (ASCs) and Office Based Labs (OBLs). Because of this collaboration, customers can access extensive product portfolios, financial solutions and exceptional service. GE Healthcare Interventional Imaging solutions are built to help our customers deliver care at a higher level for patients, which is very useful of cancer patients. This has helped the company to expand its business

North America Uterine Cancer Diagnostics Market Scope

North America uterine cancer diagnostics market is segmented into diagnostic type, type, age group, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

BY DIAGNOSTIC TYPE

  • Instrument Based
  • Procedure Based

On the basis of diagnostic type, the North America uterine cancer diagnostic market is segmented into instrument based and procedure based.

BY TYPE

  • Endometrial Cancer
  • Uterine Sarcoma

On the basis of type, the North America uterine cancer diagnostic market is segmented into endometrial cancer and uterine sarcoma.

BY AGE GROUP

  • <30 years
  • 31-40 years
  • 41-50 years
  • 51-60 years
  • >60 years

On the basis of age group, the North America uterine cancer diagnostic market is segmented into <30, 31-40, 41-50, 51-60 and >60.

BY END USER

  • Hospitals
  • Diagnostic Centers
  • Cancer Research Centers
  • Ambulatory Surgical Centers
  • Specialized Clinics
  • Others

On the basis of end user, the North America uterine cancer diagnostic market is segmented into hospitals, diagnostic centers, cancer research centers, ambulatory surgical centers, specialized clinics and others.

BY DISTRIBUTION CHANNEL

  • Direct Tenders
  • Third Party Distributors
  • Others

On the basis of distribution channel, the North America uterine cancer diagnostic market is segmented into direct tender, third party distributors and others.

Uterine Cancer Diagnostics Market

North America Uterine Cancer Diagnostics Market Regional Analysis/Insights

The North America uterine cancer diagnostics market is analyzed and market size information is provided diagnostic type, type, age group, end user and distribution channel.

The countries covered in this market report are the U.S., Canada, and Mexico.

U.S is expected to dominate the North America uterine cancer diagnostics market due to the presence of key market players in the largest consumer market with high GDP and due to its latest advanced cancer diagnostic technology and inventions in uterine cancer diagnostics.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and North America Uterine Cancer Diagnostics Market Share Analysis

North America uterine cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus on the North America uterine cancer diagnostics market.

Some of the major players operating in the North America uterine cancer diagnostics market are F-Hoffmann La Roche Ltd., Siemens Healthcare Private Limited, Narang Medical Limited, ESAOTE SPA, Olympus Corporation, Arquer Diagnostics Ltd, Guzip Biomarkers Corporation, General Electric, Canon Medical Systems ANZ Pty Limited., KARL STORZ, Medtronic, Stryker, Surtex Instruments Limited., Koninklijke Philips N.V., FUJIFILM Corporation, AED, Jalal Surgical, Integra LifeSciences, B. Braun Melsungen AG, and GRAIL among others.


SKU-

TABLE 1 NORTH AMERICA RATE OF ENDOMETRIAL CANCER (2020)

TABLE 2 U.S. (2022)

TABLE 3 U.K. (2019)

TABLE 4 GERMANY RATE OF ENDOMETRIAL CANCER (2019)

TABLE 5 POLAND RATE OF ENDOMETRIAL CANCER (2020)

TABLE 6 SINGAPORE (2020)

TABLE 7 JAPAN (2022)

TABLE 8 INDIA (2020)

TABLE 9 AUSTRALIA (2022)

TABLE 10 BRAZIL RATE OF ENDOMETRIAL CANCER (2018)

TABLE 11 ARGENTINA (2020)

TABLE 12 UAE (2020)

TABLE 13 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 14 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 16 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 17 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)

TABLE 18 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 19 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)

TABLE 20 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 21 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)

TABLE 22 NORTH AMERICA TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 23 NORTH AMERICA BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 24 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 26 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)

TABLE 27 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 28 NORTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 NORTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 30 NORTH AMERICA SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 31 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 32 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 33 NORTH AMERICA ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 34 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 35 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 36 NORTH AMERICA UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 37 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 38 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 39 NORTH AMERICA PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 40 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 41 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 42 NORTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 NORTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 44 NORTH AMERICA LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 45 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 46 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 47 NORTH AMERICA ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 48 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 49 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 50 NORTH AMERICA UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 51 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 52 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 53 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 54 NORTH AMERICA >60 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 55 NORTH AMERICA 51-60 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 56 NORTH AMERICA 41-50 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 57 NORTH AMERICA 31-40 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 58 NORTH AMERICA <30 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 59 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 60 NORTH AMERICA HOSPITALS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 61 NORTH AMERICA DIAGNOSTIC CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 62 NORTH AMERICA CANCER RESEARCH CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 63 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 64 NORTH AMERICA SPECIALIZED CLINICS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 65 NORTH AMERICA OTHERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 66 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 67 NORTH AMERICA DIRECT TENDER IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 68 NORTH AMERICA THIRD PARTY DISTRIBUTORS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 69 NORTH AMERICA OTHERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 70 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 71 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 72 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 73 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 74 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)

TABLE 75 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)

TABLE 76 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 77 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)

TABLE 78 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)

TABLE 79 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 80 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)

TABLE 81 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)

TABLE 82 NORTH AMERICA TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 83 NORTH AMERICA BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 84 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 85 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)

TABLE 86 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)

TABLE 87 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 88 NORTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 89 NORTH AMERICA SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 90 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 91 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 92 NORTH AMERICA ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 93 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 94 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 95 NORTH AMERICA UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 96 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 97 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 98 NORTH AMERICA PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 99 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 100 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 101 NORTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 102 NORTH AMERICA LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 103 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 104 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 105 NORTH AMERICA ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 106 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 107 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 108 NORTH AMERICA UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 109 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 110 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 111 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 112 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 113 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 114 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 115 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 116 U.S. ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 117 U.S. ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)

TABLE 118 U.S. ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)

TABLE 119 U.S. SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 120 U.S. SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)

TABLE 121 U.S. SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)

TABLE 122 U.S. IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 123 U.S. IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)

TABLE 124 U.S. IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)

TABLE 125 U.S. TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 126 U.S. BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 127 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 128 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)

TABLE 129 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)

TABLE 130 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 131 U.S. ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 132 U.S. SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 133 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 134 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 135 U.S. ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 136 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 137 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 138 U.S. UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 139 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 140 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 141 U.S. PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 142 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 143 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 144 U.S. UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 145 U.S. LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 146 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 147 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 148 U.S. ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 149 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 150 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 151 U.S. UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 152 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 153 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 154 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 155 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 156 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 157 CANADA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 158 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 159 CANADA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 160 CANADA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)

TABLE 161 CANADA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)

TABLE 162 CANADA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 163 CANADA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)

TABLE 164 CANADA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)

TABLE 165 CANADA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 166 CANADA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)

TABLE 167 CANADA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)

TABLE 168 CANADA TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 169 CANADA BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 170 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 171 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)

TABLE 172 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)

TABLE 173 CANADA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 174 CANADA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 175 CANADA SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 176 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 177 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 178 CANADA ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 179 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 180 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 181 CANADA UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 182 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 183 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 184 CANADA PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 185 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 186 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 187 CANADA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 188 CANADA LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 189 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 190 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 191 CANADA ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 192 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 193 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 194 CANADA UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 195 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 196 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 197 CANADA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 198 CANADA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 199 CANADA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 200 MEXICO UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 201 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 202 MEXICO ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 203 MEXICO ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)

TABLE 204 MEXICO ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)

TABLE 205 MEXICO SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 206 MEXICO SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)

TABLE 207 MEXICO SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)

TABLE 208 MEXICO IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 209 MEXICO IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)

TABLE 210 MEXICO IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)

TABLE 211 MEXICO TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 212 MEXICO BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 213 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 214 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)

TABLE 215 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)

TABLE 216 MEXICO UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 217 MEXICO ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 218 MEXICO SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 219 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 220 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 221 MEXICO ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 222 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 223 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 224 MEXICO UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 225 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 226 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 227 MEXICO PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 228 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 229 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 230 MEXICO UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 231 MEXICO LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 232 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 233 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 234 MEXICO ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 235 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 236 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 237 MEXICO UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 238 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 239 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)

TABLE 240 MEXICO UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 241 MEXICO UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 242 MEXICO UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The North America Uterine Cancer Diagnostics Market is projected to grow at a CAGR of 11.2% during the forecast period by 2030.
The future market value of the North America Uterine Cancer Diagnostics Market is expected to reach USD 7,946.03 million by 2030.
The major players in the North America Uterine Cancer Diagnostics Market are F-Hoffmann La Roche Ltd., Siemens Healthcare Private Limited, Narang Medical Limited, ESAOTE SPA, Olympus Corporation, Integra LifeSciences, Canon Medical Systems ANZ Pty Limited., etc.
The countries covered in the North America Uterine Cancer Diagnostics Market are U.S., Canada, and Mexico.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials